BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beaugerie L, Rahier JF, Kirchgesner J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 1324-1335. e2. [PMID: 32059920 DOI: 10.1016/j.cgh.2020.02.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Imperatore N, Foggia M, Patturelli M, Rispo A, Calabrese G, Testa A, Pellegrini L, Tosone G, Di Luna I, Nardone OM, Ricciolino S, Castiglione F. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol 2021;36:1859-68. [PMID: 33283312 DOI: 10.1111/jgh.15367] [Reference Citation Analysis]
2 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
3 Kroenke MA, Milton MN, Kumar S, Bame E, White JT. Immunogenicity Risk Assessment for Multi-specific Therapeutics. AAPS J 2021;23:115. [PMID: 34741215 DOI: 10.1208/s12248-021-00642-5] [Reference Citation Analysis]
4 Alameel T, Al Sulais E. Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2021;19:621-2. [PMID: 33248086 DOI: 10.1016/j.cgh.2020.04.089] [Reference Citation Analysis]
5 Klang E, Soffer S, Shachar E, Lahat A. Trends in inflammatory bowel disease infections and vaccinations in the past four decades: A high-level text mining analysis of PubMed publications. Hum Vaccin Immunother 2022;:1-6. [PMID: 35471850 DOI: 10.1080/21645515.2022.2065814] [Reference Citation Analysis]
6 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
7 Siegel CA, Christensen B, Kornbluth A, Rosh JR, Kappelman MD, Ungaro RC, Johnson DF, Chapman S, Wohl DA, Mantzaris GJ. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19. J Crohns Colitis. 2020;14:S769-S773. [PMID: 33085972 DOI: 10.1093/ecco-jcc/jjaa135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Tripathi K, Godoy Brewer G, Thu Nguyen M, Singh Y, Saleh Ismail M, Sauk JS, Parian AM, Limketkai BN. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2021:izab236. [PMID: 34718595 DOI: 10.1093/ibd/izab236] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Are patients with inflammatory bowel disease receiving adequate immunisation? Gastroenterol Hepatol 2021;44:198-205. [PMID: 33131901 DOI: 10.1016/j.gastrohep.2020.06.024] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
11 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
12 Tehrani S, Ziaie S, Kashefizadeh A, Fadaei M, Najafiarab H, Keyvanfar A. Case Report: Pneumonia in a Patient With Combined Variable Immunodeficiency: COVID-19 or Pneumocystis Pneumonia? Front Med (Lausanne) 2022;9:814300. [PMID: 35280884 DOI: 10.3389/fmed.2022.814300] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu Y, Liao R, Qiang Z, Yang W, Cao J, Zeng H. Exogenous H2S Protects Colon Cells in Ulcerative Colitis by Inhibiting NLRP3 and Activating Autophagy. DNA Cell Biol 2021;40:748-56. [PMID: 33983842 DOI: 10.1089/dna.2020.6380] [Reference Citation Analysis]
14 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]
15 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Solitano V, D'Amico F, Correale C, Peyrin-Biroulet L, Danese S. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. Br Med Bull 2020;136:107-17. [PMID: 33200781 DOI: 10.1093/bmb/ldaa033] [Reference Citation Analysis]
17 Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Reference Citation Analysis]
18 Lin TY, Lai YF, Chen PH, Chung CH, Chen CL, Chen YH, Chen JT, Kuo PC, Chien WC, Hsieh YH. Association Between Ischemic Optic Neuropathy and Inflammatory Bowel Disease: A Population-Based Cohort Study in Taiwan. Front Med (Lausanne) 2021;8:753367. [PMID: 34651004 DOI: 10.3389/fmed.2021.753367] [Reference Citation Analysis]
19 Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020;69:1335-42. [PMID: 32303609 DOI: 10.1136/gutjnl-2020-321269] [Cited by in Crossref: 153] [Cited by in F6Publishing: 135] [Article Influence: 76.5] [Reference Citation Analysis]
20 Lei HY, Ding YH, Nie K, Dong YM, Xu JH, Yang ML, Liu MQ, Wei L, Nasser MI, Xu LY, Zhu P, Zhao MY. Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomed Pharmacother 2021;133:111064. [PMID: 33378966 DOI: 10.1016/j.biopha.2020.111064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Tepasse PR, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life (Basel) 2021;11:1220. [PMID: 34833096 DOI: 10.3390/life11111220] [Reference Citation Analysis]
22 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chen R, Tie Y, Lu J, Li L, Zeng Z, Chen M, Zhang S. Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions. Cell Prolif 2022;:e13222. [PMID: 35373402 DOI: 10.1111/cpr.13222] [Reference Citation Analysis]
24 Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2512-2556.e9. [PMID: 34051985 DOI: 10.1053/j.gastro.2021.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Singh S, Heien HC, Sangaralingham L, Shah ND, Lai JC, Sandborn WJ, Moore AA. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2020. [DOI: 10.1093/ibd/izaa327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Foligné B, George F, Standaert A, Garat A, Poiret S, Peucelle V, Ferreira S, Sobry H, Muharram G, Lucau‐danila A, Daniel C. High‐dose dietary supplementation with zinc prevents gut inflammation: Investigation of the role of metallothioneins and beyond by transcriptomic and metagenomic studies. FASEB j 2020;34:12615-33. [DOI: 10.1096/fj.202000562rr] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chen G, Xie J, Liang T, Wang Y, Liao W, Song L, Zhang X. Inflammatory Bowel disease promote oral cancer and pharyngeal cancer: new evidence of Mendelian randomization. Acta Otolaryngol 2022;142:191-6. [PMID: 35195051 DOI: 10.1080/00016489.2022.2035431] [Reference Citation Analysis]
28 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
29 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]